Squamous Cell Carcinoma Clinical Trial
Official title:
Atezolizumab in Patients With Urinary Tract Squamous Cell Carcinoma: a Single Arm, Open Label, Multicentre, Phase II Clinical Trial
Atezolizumab in patients with urinary tract squamous cell carcinoma: a single-arm, open-label, multicentre, phase II clinical trial
AURORA is a phase II open-label trial of Atezolizumab in patients with urinary tract squamous cell carcinoma (UTSCC). UTSCC is the most common of the rare urinary tract cancer histologies, comprising 2.1-6.7% of urinary tract cancers overall. There are few data available to guide treatment decisions for UTSCC. The AURORA trial will test the hypothesis that PD-L1 inhibition with atezolizumab immunotherapy is clinically effective, tolerable and safe, in patients with urinary tract squamous cell carcinoma (UTSCC). Translational endpoints will aim to determine characteristics for responsiveness to this treatment. AURORA was developed on behalf of the International Rare Cancers Initiative (IRCI) and the National Cancer Research Institute Bladder and Renal Group. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT02213133 -
Selinexor Treatment of Advanced Relapsed/Refractory Squamous Cell Carcinomas
|
Phase 2 | |
| Not yet recruiting |
NCT04533321 -
A Biomarker-implemented Clinical Study Evaluating Mutations in MET and TP53 in a Population of Treatment-refractory Squamous Cell Carcinoma
|
Phase 2 | |
| Terminated |
NCT02890368 -
Trial of Intratumoral Injections of TTI-621 in Subjects With Relapsed and Refractory Solid Tumors and Mycosis Fungoides
|
Phase 1 | |
| Active, not recruiting |
NCT01232374 -
Nimotuzumab in Combination With Chemoradiation for Local Advanced Esophageal Squamous Cell Carcinoma
|
Phase 2 | |
| Completed |
NCT01208883 -
A Feasibility Study On Continuous Adaptive [18f]Fdg-Pet-Guided Radiotherapy For Head and Neck Cancer
|
Phase 1 | |
| Withdrawn |
NCT01148082 -
School Response to Families Who Have Children With Cancer
|
N/A | |
| Completed |
NCT01089803 -
Observational Study of Swallowing Function After Treatment of Advanced Laryngeal Cancer
|
N/A | |
| Terminated |
NCT00707655 -
Zalutumumab in Combination With Radiotherapy in Head and Neck Cancer Patients Ineligible for Platinum Based Chemotherapy
|
Phase 1/Phase 2 | |
| Completed |
NCT01127737 -
Warning Signs of Squamous Cell Carcinoma and Prevention of SCC by at Risk Organ Transplant Recipients
|
N/A | |
| Completed |
NCT00586040 -
Photochemical Tissue Bonding
|
Phase 2 | |
| Completed |
NCT00793169 -
Serum Concentration of Lidocaine After Local Injection During Mohs Micrographic Surgery
|
||
| Completed |
NCT00409565 -
A Phase II Trial of Cetuximab and Bevacizumab in Patients With Recurrent or Metastatic Head and Neck Cancer
|
Phase 2 | |
| Completed |
NCT00176267 -
Paclitaxel, Carboplatin And Low Dose Radiation As Induction Therapy In Locally Advanced Head And Neck Cancer
|
Phase 2 | |
| Terminated |
NCT04685798 -
Optimized Diffusion-Weighted Imaging for the Evaluation of Post-Treatment Squamous Cell Carcinoma in the Neck: Comparative Study With FDG PET/CT
|
N/A | |
| Recruiting |
NCT04370587 -
A Clinical Study of Intratumoral MVR-T3011 (T3011) Given as a Single Agent and in Combination With Intravenous Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
| Recruiting |
NCT04475952 -
Early Diagnosis of Upper Digestive Tract Disease
|
||
| Recruiting |
NCT04435938 -
A Study of SBRT for Squamous Cell Carcinoma of the Head and Neck
|
Phase 2 | |
| Not yet recruiting |
NCT05852665 -
Buccal Cancer Resection Ultrasound Guided
|
N/A | |
| Recruiting |
NCT05048459 -
Comparing Two Surveillance Approaches for People Who Have Received Treatment for HPV-associated Head and Neck Cancer and Show No Signs of Disease
|
N/A | |
| Suspended |
NCT03952585 -
De-intensified Radiation Therapy With Chemotherapy (Cisplatin) or Immunotherapy (Nivolumab) in Treating Patients With Early-Stage, HPV-Positive, Non-Smoking Associated Oropharyngeal Cancer
|
Phase 2/Phase 3 |